MARKET

NRBO

NRBO

Neurobo Pharmaceuticals Inc
NASDAQ
4.580
-0.020
-0.43%
Closed 16:00 05/21 EDT
OPEN
4.600
PREV CLOSE
4.600
HIGH
4.650
LOW
4.270
VOLUME
13.07K
TURNOVER
0
52 WEEK HIGH
6.75
52 WEEK LOW
2.889
MARKET CAP
22.47M
P/E (TTM)
-1.4047
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NRBO last week (0513-0517)?
Weekly Report · 2d ago
Buy Rating Affirmed for NeuroBo Pharmaceuticals on Promising Obesity and MASH Drug Developments
TipRanks · 5d ago
Weekly Report: what happened at NRBO last week (0506-0510)?
Weekly Report · 05/13 10:32
NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024
NeuroBo Pharmaceuticals reported results for the first quarter of 2024. The company did not report any revenue for the quarter. NeuroBo reported earnings per share of -$1.32. This was below the analyst estimate for EPS of - $1.10.
Investorplace · 05/09 17:53
Neurobo Pharmaceuticals Inc: Current report
Press release · 05/09 16:04
NeuroBo Pharmaceuticals GAAP EPS of -$1.32
NeuroBo Pharmaceuticals, Inc. Reports Q1 GAAP EPS of -$1.32. Cash was approximately $16.0 million as of March 31, 2024, compared to approximately $22.4 million at December 31, 2023. The company expects to report quarterly earnings of $0.02 per share.
Seeking Alpha · 05/09 14:49
NeuroBo Pharmaceuticals Q1 2024 GAAP EPS $(1.32) Misses $(1.10) Estimate
Benzinga · 05/09 12:47
*NeuroBo: Cash of $16.0 M Expected to Fund the Co Into 4Q >NRBO
Dow Jones · 05/09 12:07
More
About NRBO
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.

Webull offers Neurobo Pharmaceuticals Inc stock information, including NASDAQ: NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.